Brean Capital Maintains Buy Rating on Yelp (YELP) Ahead of 2Q15 Results

Go back to Brean Capital Maintains Buy Rating on Yelp (YELP) Ahead of 2Q15 Results

Pre-Open Stock Movers 07/20: (EXEL) (VSLR) (PYPL) Higher; (CRMD) (CALM) (BRCD) Lower (more...)

July 20, 2015 9:28 AM EDT

Exelixis (NASDAQ: EXEL) 50.6% HIGHER; announced positive top-line results from the primary analysis of METEOR, the phase 3 pivotal trial comparing cabozantinib to everolimus in 658 patients with metastatic renal cell carcinoma (RCC) who have experienced disease progression following treatment with a VEGF receptor tyrosine kinase inhibitor (TKI).

Vivint Solar (NYSE: VSLR) 43.6% HIGHER; SunEdison, Inc. (NYSE: SUNE), the world's largest renewable energy development company, Vivint Solar (NYSE: VSLR),... More

Barclays Downgrades Yelp (YELP) to Equalweight

July 20, 2015 6:37 AM EDT

Barclays downgraded Yelp (NYSE: YELP) from Overweight to Equalweight with a price target of $36.00 (from $50.00).

For an analyst ratings summary and ratings history on Yelp click here. For more ratings news on Yelp click here.

Shares of Yelp closed at $34.96 yesterday.

... More